226 related articles for article (PubMed ID: 23606010)
21. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
[TBL] [Abstract][Full Text] [Related]
22. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
23. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
24. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
25. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
26. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.
Imbar T; Kol S; Lossos F; Bdolah Y; Hurwitz A; Haimov-Kochman R
Hum Reprod; 2012 Mar; 27(3):753-9. PubMed ID: 22252086
[TBL] [Abstract][Full Text] [Related]
27. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
28. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
29. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
30. A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
Deng L; Li XL; Ye DS; Blockeel C; Zhou XY; Chen SL; Chen X
Curr Med Sci; 2019 Apr; 39(2):278-284. PubMed ID: 31016522
[TBL] [Abstract][Full Text] [Related]
31. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
32. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
Bassiouny YA; Dakhly DMR; Bayoumi YA; Salaheldin NM; Gouda HM; Hassan AA
Int J Gynaecol Obstet; 2018 Feb; 140(2):217-222. PubMed ID: 29055130
[TBL] [Abstract][Full Text] [Related]
34. Strategies for the management of OHSS: Results from freezing-all cycles.
Borges E; Braga DP; Setti AS; Vingris LS; Figueira RC; Iaconelli A
JBRA Assist Reprod; 2016 Mar; 20(1):8-12. PubMed ID: 27203299
[TBL] [Abstract][Full Text] [Related]
35. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
36. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
37. Ovarian stimulation for freeze-all IVF cycles: a systematic review.
Mizrachi Y; Horowitz E; Farhi J; Raziel A; Weissman A
Hum Reprod Update; 2020 Jan; 26(1):118-135. PubMed ID: 31867625
[TBL] [Abstract][Full Text] [Related]
38. GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.
Tan J; Jing C; Zhang L; Lo J; Kan A; Nakhuda G
J Assist Reprod Genet; 2020 Aug; 37(8):1939-1948. PubMed ID: 32533431
[TBL] [Abstract][Full Text] [Related]
39. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
40. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
Shrem G; Steiner N; Balayla J; Volodarsky-Perel A; Tannus S; Son WY; Dahan MH
Reprod Biomed Online; 2019 Sep; 39(3):433-438. PubMed ID: 31320288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
